Results 151 to 160 of about 5,406 (200)
Aprepitant for Oculoplastic Surgeries
Ophthalmic Plastic & Reconstructive SurgeryPurpose: Postoperative nausea and vomiting remain significant concerns in surgical care, impacting patient recovery, satisfaction, and healthcare costs. This study evaluates the efficacy of 40 mg oral aprepitant in reducing postoperative nausea and vomiting incidence and severity compared with placebo.
Kevin, Wu +2 more
openaire +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Aprepitant for Erlotinib-Induced Pruritus
New England Journal of Medicine, 2010To the Editor: Aprepitant is the first commercially available drug of a new class of neurokinin-1–receptor antagonists for treating chemotherapy-induced nausea and vomiting. The dominant ligand for the neurokinin-1 receptor is substance P.1,2 An increase in the number of neurokinin-1 receptors on keratinocytes has been found in patients with chronic ...
Bruno Vincenzi +2 more
exaly +6 more sources
Drugs, 2009
Aprepitant (Emend) is a neurokinin-1 (NK(1)) receptor antagonist that is able to alleviate the emetic effects of substance P. When combined with a standard regimen of a corticosteroid (dexamethasone) and a serotonin 5-HT(3) receptor antagonist (ondansetron), oral aprepitant (125 mg on day 1 then 80 mg once daily on days 2 and 3) was effective in the ...
Dean M Robinson, Monique P Curran
exaly +3 more sources
Aprepitant (Emend) is a neurokinin-1 (NK(1)) receptor antagonist that is able to alleviate the emetic effects of substance P. When combined with a standard regimen of a corticosteroid (dexamethasone) and a serotonin 5-HT(3) receptor antagonist (ondansetron), oral aprepitant (125 mg on day 1 then 80 mg once daily on days 2 and 3) was effective in the ...
Dean M Robinson, Monique P Curran
exaly +3 more sources
, 2016 This is a poster presented at the Natural Sciences Poster Session at Parkland College, which provides the chemical makeup, dosage, and the body\u27s response to Aprepitant, also known as Emend, a medication used to prevent acute and delayed nausea and ...
Pagan, Genesis N, Mark G. Papich
core +5 more sources
British Journal of Anaesthesia, 2007 Background: The neurokinin1 antagonist aprepitant is effective for prevention of chemotherapy-induced nausea and vomiting. We compared aprepitant with ondansetron for prevention of postoperative nausea and vomiting.
Michael Irwin, L Eberhart, T J Gan
exaly +3 more sources
Comparisons of aprepitant and ondansetron
American Journal of Health-System Pharmacy, 2007We are responding to the letter from Cavaretta and Noviasky[1][1] concerning Merck’s two Phase III studies of aprepitant 40 mg p.o. versus ondansetron 4 mg (as the hydrochloride salt) i.v. in the prevention of postoperative nausea and vomiting (PONV).[2][2],[3][3] Prophylactic ondansetron ...
Alexandra, Carides +4 more
openaire +2 more sources
Aprepitant: Review on Solubility Enhancement
Recent Advances in Drug Delivery and FormulationIntroduction: Substance P and its neurokinin (NK-1) receptors are upregulated in different pathophysiological conditions. Overexpression of the NK-1 receptor in cancer conditions has provided a promising pathway for cancer treatment. Clinically, Aprepitant (APT) is used as the only NK-1 antagonist in chemotherapy-induced nausea and vomiting (CINV ...
Lata, Kothapalli +6 more
openaire +2 more sources